CLOS
ATNM icon

Compagnie Lombard Odier SCmA’s Actinium Pharmaceuticals ATNM Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-167
Closed -$8K – 708
2017
Q1 		$8K Hold
167
– – ﹤0.01% 677
2016
Q4 		$4K Hold
167
– – ﹤0.01% 780
2016
Q3 		$7K Sell
167
-466
-74% -$23.9K ﹤0.01% 860
2016
Q2 		$33K Hold
633
– – ﹤0.01% 718
2016
Q1 		$38K Buy
633
+466
+279% +$29.4K ﹤0.01% 753
2015
Q4 		$16K Buy
+167
New +$11.1K ﹤0.01% 816

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ATNM Position: Q2 2017 in Review

Compagnie Lombard Odier SCmA sold out of Actinium Pharmaceuticals (ATNM) in Q2 2017, closing a stake of 167 shares — an estimated $8K sold.

Compagnie Lombard Odier SCmA first reported a position in ATNM in Q4 2015 and held it in 6 quarters. The position peaked at $38K in Q1 2016. 26 funds tracked by Wall St. Rank hold ATNM as of Q2 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Actinium Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 167 Actinium Pharmaceuticals shares in Q2 2017, an estimated $8K.
  • Compagnie Lombard Odier SCmA first reported a position in Actinium Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Compagnie Lombard Odier SCmA's Actinium Pharmaceuticals position peaked at $38K in Q1 2016.
  • 26 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2017, filed 14 Aug 2017.